Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study

被引：0

作者：

Chen, Han ^{[1
]}

Tang, Xinyu ^{[2
]}

Su, Wei ^{[1
]}

Li, Shuo ^{[1
]}

Yang, Ruoyun ^{[1
]}

Cheng, Hong ^{[3
]}

Zhang, Guoxin ^{[1
]}

Zhou, Xiaoying ^{[1
]}

机构：

[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanjing, Jiangsu, Peoples R China

[2] Nanjing Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Nanjing, Jiangsu, Peoples R China

[3] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurol, Nanjing, Jiangsu, Peoples R China

来源：

AGING-US | 2023年 / 15卷 / 24期

基金：

中国博士后科学基金;

关键词：

lipid-lowering drugs; aging; Mendelian randomization; INSTRUMENTAL VARIABLES; LDL-CHOLESTEROL; STATIN THERAPY; PCSK9;

D O I：

暂无

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Background: Despite the widespread use of statins, newer lipid-lowering drugs have been emerging. It remains unclear how the long-term use of novel lipid-lowering drugs affects the occurrence of cancers and age-related diseases.Methods: A drug-target Mendelian randomization study was performed. Genetic variants of nine lipid-lowering drug-target genes (HMGCR, PCKS9, NPC1L1, LDLR, APOB, CETP, LPL, APOC3, and ANGPTL3) were extracted as exposures from the summary data of Global Lipids Genetics Consortium Genome-Wide Association Studies (GWAS). GWAS summary data of cancers and noncancerous diseases were used as outcomes. The inversevariance weighted method was applied as the main statistical approach. Sensitivity tests were conducted to evaluate the robustness, pleiotropy, and heterogeneity of the results.Results: In addition to marked effects on decreased risks of atherosclerotic cardiovascular diseases, genetically proxied lipid-lowering variants of PCKS9, CETP, LPL, LDLR, and APOC3 were associated with longer human lifespans (q<0.05). Lipid-lowering variants of ANGPTL3 and LDLR were associated with reduced risks of colorectal cancer, and ANGPTL3 was also associated with lower risks of gastric cancer (q<0.05). Lipid-lowering LPL variants were associated with decreased risks of hypertension, type 2 diabetes, nonalcoholic fatty liver disease, and bladder cancer (q<0.05). Lipid-lowering variants of PCKS9 and HMGCR were associated with decreased risks of osteoporosis (q<0.05). Lipid-lowering APOB variants were associated with a decreased risk of thyroid cancer (q<0.05).Conclusions: Our study provides genetic evidence that newer nonstatin lipid-lowering agents have causal effects on decreased risks of several common cancers and cardiometabolic diseases. These data provide genetic insights into the potential benefits of newer nonstatin therapies.

引用

页码：15228 / 15242

页数：15

共 34 条

[1] ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets [J].

Akoumianakis, Ioannis ;

Zvintzou, Evangelia ;

Kypreos, Kyriakos ;

Filippatos, Theodosios D. .

CURRENT ATHEROSCLEROSIS REPORTS, 2021, 23 (05)

[2] Understanding the Basics of Meta-Analysis and How to Read a Forest Plot: As Simple as It Gets [J].

Andrade, Chittaranjan .

JOURNAL OF CLINICAL PSYCHIATRY, 2020, 81 (05)

[3] Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods [J].

Burgess, Stephen ;

Dudbridge, Frank ;

Thompson, Simon G. .

STATISTICS IN MEDICINE, 2016, 35 (11) :1880-1906

[4] Shared liver-like transcriptional characteristics in liver metastases and corresponding primary colorectal tumors [J].

Cheng, Jun ;

Song, Xuekun ;

Ao, Lu ;

Chen, Rou ;

Chi, Meirong ;

Guo, You ;

Zhang, Jiahui ;

Li, Hongdong ;

Zhao, Wenyuan ;

Guo, Zheng ;

Wang, Xianlong .

JOURNAL OF CANCER, 2018, 9 (08) :1500-1505

[5] Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians [J].

Davies, Neil M. ;

Holmes, Michael V. ;

Smith, George Davey .

BMJ-BRITISH MEDICAL JOURNAL, 2018, 362

[6] CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism [J].

Dong, Bin ;

Singh, Amar Bahadur ;

Fung, Chin ;

Kan, Kelvin ;

Liu, Jingwen .

ATHEROSCLEROSIS, 2014, 235 (02) :449-462

[7]

Evans Daniel S, 2022, Methods Mol Biol, V2547, P1, DOI 10.1007/978-1-0716-2573-6_1

[8] Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial [J].

Fitzgerald, Kevin ;

Frank-Kamenetsky, Maria ;

Shulga-Morskaya, Svetlana ;

Liebow, Abigail ;

Bettencourt, Brian R. ;

Sutherland, Jessica E. ;

Hutabarat, Renta M. ;

Clausen, Valerie A. ;

Karsten, Verena ;

Cehelsky, Jeffrey ;

Nochur, Saraswathy V. ;

Kotelianski, Victor ;

Horton, Jay ;

Mant, Timothy ;

Chiesa, Joseph ;

Ritter, James ;

Munisamy, Malathy ;

Vaishnaw, Akshay K. ;

Gollob, Jared A. ;

Simon, Amy .

LANCET, 2014, 383 (9911) :60-68

[9] Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials [J].

Fulcher, Jordan ;

Mihaylova, Borislaya ;

O'Connell, Rachel ;

Emberson, Jonathan ;

Blackwell, Lisa ;

Reith, Christina ;

Koren, Michael ;

Tonkin, Andrew ;

Ridker, Paul ;

Barnes, Elizabeth ;

Ford, Ian ;

Packard, Chris ;

Lonn, Eva ;

Wanner, Christoph ;

Koenig, Wolfgang ;

Gotto, Antonio ;

Kjekshus, John ;

Yusuf, Salim ;

Collins, Rory ;

Simes, John ;

Baigent, Colin ;

Keech, Anthony ;

de Lemos, J. ;

Braunwald, E. ;

Blazing, M. ;

Murphy, S. ;

Downs, J. R. ;

Gotto, A. ;

Clearfield, M. ;

Holdaas, H. ;

Gordon, D. ;

Davis, B. ;

Koren, M. ;

Dahlof, B. ;

Poulter, N. ;

Sever, P. ;

Knopp, R. H. ;

Fellstrom, B. ;

Jardine, A. ;

Schmieder, R. ;

Zannad, F. ;

Colhoun, H. M. ;

Betteridge, D. J. ;

Durrington, P. N. ;

Hitman, G. A. ;

Fuller, J. ;

Neil, A. ;

Sacks, F. ;

Moye, L. ;

Pfeffer, M. .

LANCET, 2019, 393 (10170) :407-415

[10] Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials [J].

Fulcher, Jordan ;

O'Connell, Rachel ;

Voysey, Merryn ;

Emberson, Jonathan ;

Blackwell, Lisa ;

Mihaylova, Borislava ;

Simes, John ;

Collins, Rory ;

Kirby, Adrienne ;

Colhoun, Helen ;

Braunwald, Eugene ;

La Rosa, John ;

Pedersen, T. R. ;

Tonkin, Andrew ;

Davis, Barry ;

Sleight, Peter ;

Franzosi, Maria Grazia ;

Baigent, Colin ;

Keech, Anthony ;

de Lemos, J. ;

Blazing, M. ;

Murphy, S. ;

Downs, J. R. ;

Gotto, A. ;

Clearfield, M. ;

Holdaas, H. ;

Gordon, D. ;

Koren, M. ;

Dahloef, B. ;

Poulter, N. ;

Sever, P. ;

Knopp, R. H. ;

Fellstroem, B. ;

Holdaas, H. ;

Jardine, A. ;

Schmieder, R. ;

Zannad, F. ;

Goldbourt, U. ;

Kaplinsky, E. ;

Colhoun, H. M. ;

Betteridge, D. J. ;

Durrington, P. N. ;

Hitman, G. A. ;

Fuller, J. ;

Neil, A. ;

Wanner, C. ;

Krane, V. ;

Sacks, F. ;

Moye, L. ;

Pfeffer, M. .

LANCET, 2015, 385 (9976) :1397-1405

← 1 2 3 4 →